KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Testosterone replacement in prostate cancer survivors with testosterone deficiency: Study protocol of a randomized controlled trial. PMID 36181480 · Andrology · 2023-Jan The record is a protocol without results and does not report a primary time-to-event efficacy endpoint, making it ineligible for inclusion in a KM digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood. PMID 36179986 · Transplant Cell Ther · 2023-Jan The record describes an analysis of health-related quality of life from a randomized phase III trial, but it is not a primary or key secondary report of a time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Anterior quadratus lumborum block does not reduce postoperative opioid consumption following laparoscopic hemicolectomy: a randomized, double-blind, controlled trial in an ERAS setting. PMID 36167477 · Reg Anesth Pain Med · 2023-Jan 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. PMID 36137735 · Ann Rheum Dis · 2023-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Cardiac Function Modifies the Impact of Heart Base Dose on Survival: A Voxel-Wise Analysis of Patients With Lung Cancer From the PET-Plan Trial. PMID 36130693 · J Thorac Oncol · 2023-Jan The report is from a randomized, multicenter trial (PET-Plan) with an oncology population (NSCLC) and a primary time-to-event endpoint (overall survival). However, the intervention described is radiotherapy (a non-drug intervention), and the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata or abstract. It is a dosimetric analysis within a trial, not a primary report of a drug-containing arm. Therefore, it does not meet the requirement for a drug-containing intervention and a confirmed definitive trial phase.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Effect of Patient Positioning on Ureteral Efflux During Intraoperative Cystoscopy: A Randomized Controlled Trial. PMID 36103970 · J Minim Invasive Gynecol · 2023-Jan 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Covered versus uncovered double bare self-expandable metal stent for palliation of unresectable extrahepatic malignant biliary obstruction: a randomized controlled multicenter trial. PMID 36084714 · Gastrointest Endosc · 2023-Jan The trial is a randomized, multicenter, Phase II/III study comparing two types of metal stents for palliation of malignant biliary obstruction. It includes overall survival (a time-to-event endpoint). However, the intervention is a device (stent) with no drug-containing component, which violates the mandatory drug intervention criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Proof of Principle of Combining Fluorescence-Guided Surgery with Photoimmunotherapy to Improve the Outcome of Pancreatic Cancer Therapy in an Orthotopic Mouse Model. PMID 36057899 · Ann Surg Oncol · 2023-Jan The study is an animal model (mice) preclinical trial, not a human clinical trial. While it is randomized and involves a drug-containing intervention (antibody-fluorophore conjugate for photoimmunotherapy), it is excluded because it is preclinical. The primary endpoint is recurrence rate and tumor weight, not a time-to-event endpoint like OS/PFS/DFS/EFS/RFS/TTP with Kaplan-Meier or HR analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609. PMID 36029412 · Qual Life Res · 2023-Jan This is a secondary analysis of a Phase III randomized oncology trial, but it focuses on patient-reported tolerability and quality of life, not on a primary/key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, or HR from Kaplan-Meier analysis. Therefore, it does not meet the requirement for a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Surgical resection after neoadjuvant durvalumab and radiation is feasible and safe in non-small cell lung cancer: Results from a randomized trial. PMID 36028357 · J Thorac Cardiovasc Surg · 2023-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Cidan Capsule in Combination with Adjuvant Transarterial Chemoembolization Reduces Recurrence Rate after Curative Resection of Hepatocellular Carcinoma: A Multicenter, Randomized Controlled Trial. PMID 35915317 · Chin J Integr Med · 2023-Jan The study is an original, randomized, human oncology trial with time-to-event efficacy endpoints. However, it is excluded because the primary intervention under evaluation is not a standard drug-containing regimen (it is an investigational capsule combined with a non-drug procedure), and the trial phase is not explicitly confirmed as Phase III/IIIb or II/III in the provided text.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical outcomes of laparoscopic-assisted natural orifice specimen extraction colectomy using a Cai tube for left-sided colon cancer: a prospective randomized trial. PMID 35906459 · Surg Endosc · 2023-Jan 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial. PMID 35900699 · Pharmacoecon Open · 2023-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Incidental findings on routine preoperative noncontrast chest computed tomography and chest radiography prior to cardiac surgery in the multicenter randomized controlled CRICKET study. PMID 35852576 · Eur Radiol · 2023-Jan The record is a randomized, multicenter, primary study, but it is not an oncology drug trial. It evaluates the diagnostic yield of preoperative CT scanning in cardiac surgery patients. The intervention is non-drug (imaging), and the endpoints are diagnostic (incidental findings, surgical delay) rather than time-to-event efficacy outcomes (OS, PFS, etc.). Therefore, it does not meet the eligibility criteria for inclusion in the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Protocol for a randomised controlled trial on impact of comprehensive geriatric and supportive assessment versus standard care in older adults with cancer undergoing curative treatment: The Geriatric Oncology SuPportive clinic for ELderly (GOSPEL) study. PMID 35843845 · J Geriatr Oncol · 2023-Jan 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Development and validation of tumor-size-stratified prognostic nomograms for patients with uterine sarcoma: A SEER database analysis. PMID 35841316 · Cancer Med · 2023-Jan The study is a retrospective analysis of a SEER database to develop prognostic nomograms for uterine sarcoma. While it is a human oncology study with a time-to-event endpoint (overall survival) and reports original results, it is not a Phase III/IIIb or Phase II/III randomized trial of a drug-containing intervention. The publication type is 'Randomized Controlled Trial', but this refers to the random split of the cohort into training/validation sets, not a clinical trial randomizing patients to a drug vs. control. The study lacks any drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Intraductal papillary carcinoma of breast with invasion: A nomogram and survival from the analysis of the SEER database. PMID 35837839 · Cancer Med · 2023-Jan The study is an observational analysis of registry data (SEER database) for a nomogram, not a Phase III/IIIb or Phase II/III randomized controlled trial with a drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Postoperative tegafur-uracil for stage I lung adenocarcinoma: first real-world data with an exploratory subgroup analysis. PMID 35780275 · Surg Today · 2023-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Embracing anti-PD-1 immunotherapy in the treatment of esophageal cancer: Implications of positive phase III trials in advanced and resected esophageal cancer. PMID 35680471 · J Formos Med Assoc · 2023-Jan The record is a title-only entry with an empty abstract, and the title indicates it is likely a review or commentary on phase III trials, not a primary result report of a single randomized trial with a time-to-event endpoint. Key criteria (randomization, time_to_event, original_result) cannot be established from the provided metadata.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Dynamic peripheral blood immune cell markers for predicting the response of patients with metastatic cancer to immune checkpoint inhibitors. PMID 35661905 · Cancer Immunol Immunother · 2023-Jan The record is an oncology RCT with human subjects, a drug intervention (ICIs), and time-to-event endpoints (OS, PFS). However, the trial phase is not explicitly established as Phase III/IIIb or Phase II/III, which is a required criterion for eligibility. Furthermore, the primary focus is on developing a predictive biomarker signature, which may not align with the requirement for a 'definitive' Phase III drug-efficacy trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Endoscope-Assisted Resection of Benign Parotid Tumors via Concealed Post-Auricular Sulcus Incision. PMID 35460273 · Laryngoscope · 2023-Jan The study is an oncology-related randomized trial in humans with original results, but it is excluded because it involves a non-drug (surgical) intervention only, investigates a benign tumor, and does not have a time-to-event efficacy endpoint (OS, PFS, etc.). The intervention is endoscopic surgical technique vs. conventional surgery, with no drug component.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL). PMID 35381164 · Cancer Res Treat · 2023-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Neoadjuvant therapy with immunoagent (nivolumab) or placebo plus chemotherapy followed by surgery and adjuvant treatment in subjects with resectable esophageal squamous cell carcinoma: study protocol of a randomized, multicenter, double blind, phase II trial (NATION-2203 trial). PMID 36910109 · J Thorac Dis · 2023-Feb-28 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Influence of opioid analgesia type on circulating tumor cells in open colorectal cancer surgery (POACC-1): study protocol for a prospective randomized multicenter controlled trial. PMID 36855089 · BMC Anesthesiol · 2023-Feb-28 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase II trial. PMID 36854604 · BMJ Open · 2023-Feb-28 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effect of goal-directed fluid therapy based on plasma colloid osmotic pressure on the postoperative pulmonary complications of older patients undergoing major abdominal surgery. PMID 36849953 · World J Surg Oncol · 2023-Feb-28 The study is a randomized trial in oncology patients but does not report a time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or HR. It assesses short-term postoperative complications, and the intervention is goal-directed fluid therapy (not a drug-containing regimen). Phase is not specified.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Neoadjuvant chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Meta-analysis and trial sequential analysis of randomized controlled trials. PMID 36536501 · Ann Hepatobiliary Pancreat Surg · 2023-Feb-28 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Yanggan Jian in Hepatitis B Virus-related Decompensated Cirrhosis: A Randomized, Double-blind, Controlled Trial. PMID 36406328 · J Clin Transl Hepatol · 2023-Feb-28 The study is a randomized controlled trial in humans with original results, but it is not an oncology study (focuses on decompensated cirrhosis, not malignant neoplasm). The intervention is a traditional Chinese medicine (Yanggan Jian), which does not meet the 'drug-containing intervention' criterion for a pharmaceutical agent. The primary endpoint is a clinical score reduction (CTP score), not a time-to-event efficacy endpoint (OS, PFS, etc.). The phase is not specified as III/IIIb or II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guerin for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Randomized Controlled Trial. PMID 35689462 · Urol J · 2023-Feb-27 Study is an oncology RCT with a drug intervention and reports original results, but does not meet key eligibility criteria: it lacks an explicit Phase III or definitive phase designation, and its primary endpoint is recurrence rate at one year (a dichotomous count), not a time-to-event measure (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier analysis or hazard ratio.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial. PMID 36823150 · Signal Transduct Target Ther · 2023-Feb-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Movement and health beyond care, MoviS: study protocol for a randomized clinical trial on nutrition and exercise educational programs for breast cancer survivors. PMID 36814313 · Trials · 2023-Feb-22 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Author Correction: Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. PMID 36813827 · NPJ Digit Med · 2023-Feb-22 This is a published erratum for an article on a randomized phase III trial in prostate cancer. As an erratum, it is not an original report of trial results. The provided record lacks an abstract or sufficient text to verify human subjects, drug intervention, or a primary time-to-event efficacy endpoint (e.g., OS, PFS, KM, HR). Therefore, it does not meet the criteria for an original formal-result report of a definitive randomized trial with the required endpoint.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Lidocaine for Neuropathic Cancer Pain (LiCPain): study protocol for a mixed-methods pilot study. PMID 36810169 · BMJ Open · 2023-Feb-21 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
[Construction and evaluation of an artificial intelligence-based risk prediction model for death in patients with nasopharyngeal cancer]. PMID 36946048 · Nan Fang Yi Ke Da Xue Xue Bao · 2023-Feb-20 The record describes a prognostic model development and validation study using retrospective SEER database data and a small external clinical cohort. It is not a randomized clinical trial evaluating a drug intervention for efficacy. While it has a randomized split for analysis, there is no drug intervention, no therapeutic trial phase, and no time-to-event efficacy endpoint (OS, PFS, etc.) or Kaplan-Meier/HR results reported.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. PMID 36791474 · J Clin Oncol · 2023-Feb-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial. PMID 36508302 · J Clin Oncol · 2023-Feb-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Mepitel Film for the Prevention of Acute Radiation Dermatitis in Breast Cancer: A Randomized Multicenter Open-Label Phase III Trial. PMID 36493331 · J Clin Oncol · 2023-Feb-20 The study is a randomized Phase III trial in breast cancer patients, but it evaluates a medical device (Mepitel Film) for preventing acute radiation dermatitis. The primary endpoint is the incidence of grade 2/3 dermatitis (a toxicity/safety outcome), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it does not meet the drug-intervention or time-to-event criteria.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. PMID 36367998 · J Clin Oncol · 2023-Feb-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. PMID 36260832 · J Clin Oncol · 2023-Feb-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. PMID 36223558 · J Clin Oncol · 2023-Feb-20 The record describes a Phase III randomized trial (CheckMate 227) with a drug-containing intervention (nivolumab plus ipilimumab vs. chemotherapy) and a primary time-to-event efficacy endpoint (5-year overall survival). The abstract confirms the randomized design, human participants, oncology focus, and original result reporting. The phase is inferred from the trial name (CheckMate 227 is known as a Phase III trial), and the abstract's methods and results support definitive Phase III evidence. The report type is primary, as it presents 5-year survival outcomes from the trial.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 3 Figure · 16 Panel · risk visible
Breast Cancer: How Hippotherapy Bridges the Gap between Healing and Recovery-A Randomized Controlled Clinical Trial. PMID 36831658 · Cancers (Basel) · 2023-Feb-19 The study is a randomized controlled trial in breast cancer but fails eligibility: 1) Intervention is hippotherapy (non-drug), 2) Primary endpoint is quality of life (not time-to-event), 3) Phase not confirmed as Phase III/IIIb or II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer. PMID 35906831 · Clin Infect Dis · 2023-Feb-18 The record explicitly describes a randomized trial with a primary OS endpoint in human oncology patients, but the phase (Phase III/IIIb or Phase II/III) is not stated in the provided metadata or abstract. The phase is required for eligibility and cannot be inferred, so eligibility is indeterminate.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Bilateral prophylactic mastectomy: should we preserve the pectoral fascia? Protocol of a Dutch double blinded, prospective, randomised controlled pilot study with a within-subject design (PROFAS). PMID 36806067 · BMJ Open · 2023-Feb-17 This is a protocol for a randomized pilot study comparing surgical techniques (pectoral fascia removal vs preservation) in bilateral prophylactic mastectomy. It is a surgical-only intervention with no drug component, not a Phase III trial, and its primary endpoint is drain volume (not a time-to-event efficacy endpoint like OS, PFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial. PMID 36441798 · Clin Cancer Res · 2023-Feb-16 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study. PMID 36108304 · Blood · 2023-Feb-16 The study is a phase 2/3 trial in acute lymphoblastic leukemia with a drug intervention (JZP458) and reports original efficacy results. However, it is not randomized and does not have a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The primary efficacy endpoint is pharmacodynamic (proportion maintaining adequate nadir serum asparaginase activity).
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Obstructive Sleep Apnoea and Cardiac Arrhythmias (OSCA) trial: a nested cohort study using injectable loop recorders and Holter monitoring in patients with obstructive sleep apnoea. PMID 36792325 · BMJ Open · 2023-Feb-15 The study is a protocol for a nested cohort study in obstructive sleep apnoea (non-oncology). It is randomized but does not involve a drug intervention (intervention is an implantable loop recorder/standard care). It is not a Phase III/IIIb or Phase II/III randomized trial of a drug. The primary endpoint is arrhythmia detection (incidence), not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The report is a protocol, not a primary result report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A New Option for Pain Prevention Using a Therapeutic Virtual Reality Solution for Bone Marrow Biopsy (REVEH Trial): Open-Label, Randomized, Multicenter, Phase 3 Study. PMID 36790852 · J Med Internet Res · 2023-Feb-15 Study is a randomized Phase 3 trial in hemopathy with a drug intervention (MEOPA), but the primary and secondary endpoints are pain, anxiety, and tolerance scores, not a time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, TTP, or analysis via Kaplan-Meier/HR.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prostate cancer incidence in men with prostate-specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer. PMID 36056577 · Int J Cancer · 2023-Feb-15 The record is a randomized, human, oncology study reporting time-to-event results, but it does not meet the key eligibility criterion of having a drug-containing intervention. The study evaluates a screening strategy, not a therapeutic drug. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
User Experiences in a Digital Intervention to Support Total Skin Self-examination by Melanoma Survivors: Nested Qualitative Evaluation Embedded in a Randomized Controlled Trial. PMID 37632942 · JMIR Dermatol · 2023-Feb-13 The record describes a nested qualitative evaluation within a randomized trial of a digital intervention for melanoma survivors. It is not a report of a drug-containing Phase III/IIIb trial with a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pre-CCRT 18-fluorodeoxyglucose PET-CT improves survival in patients with advanced stages p16-negative oropharyngeal squamous cell carcinoma via accurate radiation treatment planning. PMID 36782296 · J Otolaryngol Head Neck Surg · 2023-Feb-13 The study is a human oncology randomized trial with a time-to-event endpoint, but it compares a diagnostic intervention (pre-CCRT 18FDG PET-CT vs. non-pre-CCRT PET-CT) to a standard of care, not a drug-containing intervention. The phase is not specified as Phase III/IIIb or Phase II/III in the metadata or abstract, and the publication type does not confirm it as a definitive randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -